Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Human Molecular Genetics|March 24, 2017
Golgi-retained Cx32 mutants interfere with gene addition therapy for CMT1XStyliana Kyriakoudi, Irene Sargiannidou, Alexia Kagiava, et al.
Neuropharmacology|June 6, 2015
Oxaliplatin-induced neurotoxicity is mediated through gap junction channels and hemichannels and can be prevented by octanolAlexia Kagiava, George Theophilidis, Irene Sargiannidou, et al.
Journal of the Peripheral Nervous System : JPNS|March 25, 2023
Charcot-Marie-Tooth neuropathies: Current gene therapy advances and the route toward translationMarina Stavrou, Alexia Kagiava, Irene Sargiannidou, et al.
International Journal of Molecular Sciences|July 2, 2021
Emerging Therapies for Charcot-Marie-Tooth Inherited NeuropathiesMarina Stavrou, Irene Sargiannidou, Elena Georgiou, et al.
Ebiomedicine|May 14, 2026
Progress and challenges in intrathecal gene therapy for neurological disordersAlexia Kagiava, Xin Chen, Richard S Finkel, et al.
Human Molecular Genetics|December 20, 2014
Transgenic replacement of Cx32 in gap junction-deficient oligodendrocytes rescues the phenotype of a hypomyelinating leukodystrophy modelNatasa Schiza, Irene Sargiannidou, Alexia Kagiava, et al.
Annals of Neurology|May 27, 2015
Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth diseaseIrene Sargiannidou, Alexia Kagiava, Stavros Bashiardes, et al.
Neurotoxicology|November 7, 2015
Differential effects of lacosamide, phenytoin and topiramate on peripheral nerve excitability: An ex vivo electrophysiological studyGeorgia Zafeiridou, Martha Spilioti, Alexia Kagiava, et al.
The Journal of Gene Medicine|November 14, 2014
Gene delivery targeted to oligodendrocytes using a lentiviral vectorAlexia Kagiava, Irene Sargiannidou, Stavros Bashiardes, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 7, 2025
A dose escalation and safety study of AAVrh10-mediated Schwann cell-targeted gene therapy for CMT1XMelina Christou, Irene Sargiannidou, Revekka Papacharalambous, et al.
Pageof 4